PHASE I CLINICAL TRIAL OF THE TARGETED CHEMOTHERAPEUTIC DRUG, FOLATE-TUBULYSIN, IN DOGS WITH URINARY TRACT TRANSITIONAL CELL CARCINOMA (VCS Award Winner)

摘要

Targeted chemotherapy can include repurposing drugs previously considered clinically irrelevant due to marked toxicity and low therapeutic index. Tubulysin is one such drug with compelling antiproliferative activity in vitro, but poor tolerability invivo. High affinity folate receptor (FR) expression has previously been found in canine transitional cell carcinoma (TCC) and serve as a druggable target. A phase I clinical trial of Folate-Tubulysin was conducted in dogs with urinary tract TCC.